WorksheetsPRCC_2MT-P4
Total questions: 137
Worksheet time: 1hrs 9mins
Name
Class
Date
1.
Develops when pancreas stops and producing enough of the hormones called insulin
a)
Typ 3C Diabetes
b)
Gestational diabetes
c)
Endocrine disorders
d)
Drugs or chemical induces of B-cell dysfunction
e)
Impair insulin action
2.
Due to an illness or condition that affects or damages the pancreas or removed
a)
Typ 3C Diabetes
b)
Gestational diabetes
c)
Endocrine disorders
d)
Drugs or chemical induces of B-cell dysfunction
e)
Impair insulin action
3.
Causes: acute or chronic pancreatitis, pancreatic cancer, cystic fibrosis, hemochromatosis, and surgery
a)
Typ 3C Diabetes
b)
Gestational diabetes
c)
Endocrine disorders
d)
Drugs or chemical induces of B-cell dysfunction
e)
Impair insulin action
4.
Impaired ability to metabolize carbohydrate usually caused by a deficiency of insulin, metabolic or hormonal
a)
Typ 3C Diabetes
b)
Gestational diabetes
c)
Endocrine disorders
d)
Drugs or chemical induces of B-cell dysfunction
e)
Impair insulin action
5.
Occurs during pregnancy and disappears after delivery but, in some cases, returned years later
a)
Typ 3C Diabetes
b)
Gestational diabetes
c)
Endocrine disorders
d)
Drugs or chemical induces of B-cell dysfunction
e)
Impair insulin action
6.
If she was not found to have _ during the initial screening, the woman should be retested at 21 to 28 weeks of gestation
a)
Typ 3C Diabetes
b)
Gestational diabetes
c)
Endocrine disorders
d)
Drugs or chemical induces of B-cell dysfunction
e)
Impair insulin action
7.
Down syndrome
a)
Genetic syndromes
b)
Endocrine disorders
c)
Drugs or chemical induces of B-cell dysfunction
d)
Impair insulin action
8.
Klinefelter's syndrome
a)
Genetic syndromes
b)
Endocrine disorders
c)
Drugs or chemical induces of B-cell dysfunction
d)
Impair insulin action
9.
Rabson-Mendegall syndrome
a)
Genetic syndromes
b)
Endocrine disorders
c)
Drugs or chemical induces of B-cell dysfunction
d)
Impair insulin action
10.
Leprechaunism
a)
Genetic syndromes
b)
Endocrine disorders
c)
Drugs or chemical induces of B-cell dysfunction
d)
Impair insulin action
11.
Huntington's chorea
a)
Genetic syndromes
b)
Endocrine disorders
c)
Drugs or chemical induces of B-cell dysfunction
d)
Impair insulin action
12.
Turner's syndrome
a)
Genetic syndromes
b)
Endocrine disorders
c)
Drugs or chemical induces of B-cell dysfunction
d)
Impair insulin action
13.
Cushing's syndrome
a)
Genetic syndromes
b)
Endocrine disorders
c)
Drugs or chemical induces of B-cell dysfunction
d)
Impair insulin action
14.
Pheochromocytoma
a)
Genetic syndromes
b)
Endocrine disorders
c)
Drugs or chemical induces of B-cell dysfunction
d)
Impair insulin action
15.
Acromegaly
a)
Genetic syndromes
b)
Endocrine disorders
c)
Drugs or chemical induces of B-cell dysfunction
d)
Impair insulin action
16.
Hyperthyroidism
a)
Genetic syndromes
b)
Endocrine disorders
c)
Drugs or chemical induces of B-cell dysfunction
d)
Impair insulin action
17.
Thiazides
a)
Genetic syndromes
b)
Endocrine disorders
c)
Drugs or chemical induces of B-cell dysfunction
d)
Impair insulin action
18.
Glucocorticoids
a)
Genetic syndromes
b)
Endocrine disorders
c)
Drugs or chemical induces of B-cell dysfunction
d)
Impair insulin action
19.
Dilantin
a)
Genetic syndromes
b)
Endocrine disorders
c)
Drugs or chemical induces of B-cell dysfunction
d)
Impair insulin action
20.
Pentamidine
a)
Genetic syndromes
b)
Endocrine disorders
c)
Drugs or chemical induces of B-cell dysfunction
d)
Impair insulin action
21.
If she was not found to have GDM during the initial screening, the woman should be retested at ___ weeks of gestation
a)
20 to 25 weeks
b)
21 to 28 weeks
c)
24 to 48 weeks
22.
Screening: GCT
a)
1 hr
b)
2 hrs
c)
3 hrs
d)
4 hrs
e)
5 hrs
23.
Screening: 1 hr GCT (_g)
a)
25g
b)
50g
c)
75g
d)
100g
24.
What is tested in screening GDM?
a)
Whole blood
b)
Serum
c)
Plasma
d)
Urine
25.
What is the specimen of choice in HbA1C? (EDTA);non-fast
a)
Whole blood
b)
Serum
c)
Plasma
d)
Urine
26.
Standard specimen for glucose methodologies
a)
Whole blood
b)
Serum
c)
Venous Plasma
d)
Urine
27.
Fasting glucose in whole blood is _ lower than in serum or plasma
a)
10 to 15%
b)
15 to 20%
c)
20 to 25%
28.
an OGTT is performed if glucose levels is...
a)
>=126 mg/dL
b)
>=140 mg/dL
c)
>= 92 mg/dL
d)
>= 180 mg/dL
e)
>=153 mg/dL
29.
What is the One-step method 1-hour plasma glucose diagnostic criteria for (GDM)?
a)
>=126 mg/dL
b)
>=140 mg/dL
c)
>= 92 mg/dL
d)
>= 180 mg/dL
e)
>=153 mg/dL
30.
What is the One-step method 2-hour plasma glucose diagnostic criteria for (GDM)?
a)
>=126 mg/dL
b)
>=140 mg/dL
c)
>= 92 mg/dL
d)
>= 180 mg/dL
e)
>=153 mg/dL
31.
One step method glucose load
a)
50g
b)
75g
c)
100g
32.
Two step method step 1 glucose load
a)
50g
b)
75g
c)
100g
33.
Two step method step 2 glucose load
a)
50g
b)
75g
c)
100g
34.
What is the two-step method 3-hour plasma glucose diagnostic criteria for (GDM)?
a)
>=92 mg/dL
b)
>=140 mg/dL
c)
>= 155 mg/dL
d)
>= 180 mg/dL
e)
>=95 mg/dL
35.
In the two step method, If the 1-h PG is ≥___ mg/dL, proceed to Step 2.
a)
>=92 mg/dL
b)
>=140 mg/dL
c)
>= 155 mg/dL
d)
>= 180 mg/dL
e)
>=95 mg/dL
36.
What is the two-step method 2-hour plasma glucose diagnostic criteria for (GDM)?
a)
>=92 mg/dL
b)
>=140 mg/dL
c)
>= 155 mg/dL
d)
>= 180 mg/dL
e)
>=95 mg/dL
37.
What is the two-step method 1-hour plasma glucose diagnostic criteria for (GDM)?
a)
>=92 mg/dL
b)
>=140 mg/dL
c)
>= 155 mg/dL
d)
>= 180 mg/dL
e)
>=95 mg/dL
38.
What is the two-step method fasting plasma glucose diagnostic criteria for (GDM)?
a)
>=92 mg/dL
b)
>=140 mg/dL
c)
>= 155 mg/dL
d)
>= 180 mg/dL
e)
>=95 mg/dL
39.
What is the one-step method fasting plasma glucose diagnostic criteria for (GDM)?
a)
>=92 mg/dL
b)
>=140 mg/dL
c)
>= 155 mg/dL
d)
>= 180 mg/dL
e)
>=95 mg/dL
40.
Separation duration in whole blood (glucose testing)
a)
<15 minutes
b)
<20 minutes
c)
<30 minutes
d)
<45 minutes
41.
Preservative such as __ is used if SUNSEPARATED for more than 30 minutes.
a)
Citrate
b)
Sodium fluoride
c)
Heparin
d)
EDTA
42.
Patient fasting hours: glucose
a)
8 to 10 hours
b)
7 to 10 hours
c)
8 to 12 hours
d)
9 to 12 hours
43.
Sodium fluoride preserves glucose for up to how many days along with its inhibition to bacterial growth?
a)
1 day
b)
2 days
c)
3 days
d)
4 days
e)
5 days
44.
Glucose is metabolized at this temperature
a)
Room temperature (20 to 25 degree Celsius)
b)
Refrigerated temperature (4 degree Celsius)
45.
Glucose is 7 mg/dL lower at this temperature
a)
Room temperature (20 to 25 degree Celsius)
b)
Refrigerated temperature (4 degree Celsius)
46.
Glucose is 2 mg/dL higher at this temperature
a)
Room temperature (20 to 25 degree Celsius)
b)
Refrigerated temperature (4 degree Celsius)
47.
WBC and RBC metabolized glucose resulting to __ in clotted uncentrifuged blood
a)
Decrease value
b)
Higher rate of metabolism
48.
bacterial contamination & leukocytosis
a)
Decrease value
b)
Higher rate of metabolism
49.
It is requested during insulin shot and hyperglycemic ketonic coma
a)
Random Blood Sugar (RBS)
b)
Fasting Blood Sugar (FBS)
c)
2-hour post prandial blood sugar (PPBS)
d)
Glucose tolerance test (GTT)
50.
It is a measure of overall glucose homeostasis
a)
Random Blood Sugar (RBS)
b)
Fasting Blood Sugar (FBS)
c)
2-hour post prandial blood sugar (PPBS)
d)
Glucose tolerance test (GTT)
51.
It measures how well the body metabolizes glucose
a)
Random Blood Sugar (RBS)
b)
Fasting Blood Sugar (FBS)
c)
2-hour post prandial blood sugar (PPBS)
d)
Glucose tolerance test (GTT)
52.
It is a multiple blood sugar test, performed to diagnose GDM; not recommended for routine clinical use
a)
Random Blood Sugar (RBS)
b)
Fasting Blood Sugar (FBS)
c)
2-hour post prandial blood sugar (PPBS)
d)
Glucose tolerance test (GTT)
53.
Bicarbonate and total CO2 are ___ due to kussmaul-kien respiration or deep respirations
a)
Increased
b)
Decreased
54.
Bicarbonate and total CO2 are decreased due to ___-kien respiration or deep respirations
a)
Kissmaul
b)
Kussmaul
c)
Kessmaul
d)
Kussmaule
55.
Other associations of DM include severe dehydration, electrolyte imbalance, increased BUN, and creatinine. As well as hyperosmolar serum osmolality.
a)
True
b)
False
56.
Single dose OGTT
a)
Janney-Isaac Method
b)
Exton Rose Method
57.
Most common OGTT method
a)
Janney-Isaac Method
b)
Exton Rose Method
58.
Divided dose; OGTT
a)
Janney-Isaac Method
b)
Exton Rose Method
59.
OGTT requires patient to be
a)
Unconscious
b)
Ambulatory
c)
Emergency
d)
Healthy
60.
2-hr PG (OGTT) requires CHO intake of >= __g for 3 days PRIOR to testing
a)
50g
b)
75g
c)
100g
d)
150g
61.
World Health Organization (WHO) standard glucose load
a)
50g or 1.50g/kg BW
b)
75g or 1.75g/kg BW
c)
100g or 2g/kg BW
d)
150g or 2.5g/kg BW
62.
OGTT requires fasting for...
a)
8 to 12 hours
b)
8 to 14 hours
c)
10 to 12 hours
d)
9 to 12 hours
63.
OGTT requires unrestricted diet of 150g CHO/day for _ days PRIOR to testing
a)
1 day
b)
2 days
c)
3 days
d)
4 days
64.
Used for diabetic patients with gastrointestinal disorders
a)
Oral glucose tolerance test
b)
Intravenous glucose tolerance test
65.
Diagnosis criteria for DM: HbA1C
a)
>=6.5%
b)
>=126 mg/dL
c)
>=200 mg/dL with symptoms of DM
d)
>=200 mg/dL
66.
Diagnosis criteria for DM: Fasting plasma glucose
a)
>=6.5%
b)
>=126 mg/dL
c)
>=200 mg/dL with symptoms of DM
d)
>=200 mg/dL
67.
Diagnosis criteria for DM: RBS/Casual plasma glucose
a)
>=6.5%
b)
>=126 mg/dL
c)
>=200 mg/dL with symptoms of DM
d)
>=200 mg/dL
68.
Diagnosis criteria for DM: OGTT 2-hr post glucose load (75g)
a)
>=6.5%
b)
>=126 mg/dL
c)
>=200 mg/dL with symptoms of DM
d)
>=200 mg/dL
69.
Pre-diabetes FPG
a)
100 to 125 mg/dL
b)
140 to 199 mg/dL
c)
5.7 to 6.4%
70.
Pre-diabetes in 2-hrs PG (OGTT)
a)
100 to 125 mg/dL
b)
140 to 199 mg/dL
c)
5.7 to 6.4%
71.
Pre-diabetes in HBA1C
a)
100 to 125 mg/dL
b)
140 to 199 mg/dL
c)
5.7 to 6.4%
72.
Normal range of RPG
a)
<200 mg/dL
b)
<100 mg/dL
c)
<140 mg/dL
73.
Normal range of FPG
a)
<200 mg/dL
b)
<100 mg/dL
c)
<140 mg/dL
74.
Normal range of OGTT
a)
<200 mg/dL
b)
<100 mg/dL
c)
<140 mg/dL
75.
most commonly analyzed using POCT devices at home or at the patient’s bedside; 3-4 times daily for type 1 DM patients according to ADA guidelines
a)
Whole blood glucose
b)
Glycated hemoglobin
c)
Fructosamine
d)
Microalbuminuria
76.
Hb A with glucose irreversibly attached to one or both N-terminal valines of the β-chains
a)
Whole blood glucose
b)
Glycated hemoglobin
c)
Fructosamine
d)
Microalbuminuria
77.
provides an index of average blood glucose levels over the past 2 to 3 months
a)
Whole blood glucose
b)
Glycated hemoglobin
c)
Fructosamine
d)
Microalbuminuria
78.
Unreliable in px with hemolytic disorders or abnormal RBC lifespan
a)
Whole blood glucose
b)
Glycated hemoglobin
c)
Fructosamine
d)
Microalbuminuria
79.
has the advantage of using serum samples but is unreliable when serum albumin level is <= 3g/dL
a)
Whole blood glucose
b)
Glycated hemoglobin
c)
Fructosamine
d)
Microalbuminuria
80.
early indicator of diabetic nephropathy
a)
Whole blood glucose
b)
Glycated hemoglobin
c)
Fructosamine
d)
Microalbuminuria
81.
persistent albuminuria in two out of three urine collections of 20 to 200 μg/min, 30 to 300 mg/24 h, or an albumin–creatinine ratio of 30 to 300 μg/mg or 3.5–30 mg/mmol within a 3- to 6-month period
a)
Whole blood glucose
b)
Glycated hemoglobin
c)
Fructosamine
d)
Microalbuminuria
82.
Reference range of fructosamine
a)
205 to 275 mmol/L
b)
205 to 285 mmol/L
c)
200 to 250 mmol/L
d)
150 to 200 mmol/L
83.
ADA glycemic goal:
a)
<7%
b)
>12%
c)
<6.9%
d)
>6.9%
84.
HbA1c indicating poor control
a)
<7%
b)
>12%
c)
<6.9%
d)
>6.9%
85.
Specific for glucose
a)
Enzymatic method
b)
Glucose Oxidase method
c)
Hexokinase method
d)
Glycosylated hemoglobin
86.
Reference range for HbA1C
a)
5.7 to 6.4%
b)
>=6.5%
c)
1%
d)
4 to 6%
e)
<7%
87.
Effective treatment range for HbA1C
a)
5.7 to 6.4%
b)
>=6.5%
c)
1%
d)
4 to 6%
e)
<7%
88.
For every _% change in HbA1C valuthere a 35 mg/dL INCREASE in glucose
a)
5.7 to 6.4%
b)
>=6.5%
c)
1%
d)
4 to 6%
e)
<7%
89.
Pre-diabetes
a)
5.7 to 6.4%
b)
>=6.5%
c)
1%
d)
4 to 6%
e)
<7%
90.
__% on atleast two occasion indicative of diabetes mellitus
a)
5.7 to 6.4%
b)
>=6.5%
c)
1%
d)
4 to 6%
e)
<7%
91.
It measures the Beta-D glucose
a)
Glucose Oxidase method
b)
Polarographic glucose oxidase
c)
Hexokinase method
d)
Glucose dehydrogenase method
92.
Saifer-gernstendfield method
a)
Glucose Oxidase method
b)
Colorimetric Glucose Oxidase method
c)
Polarographic glucose oxidase
d)
Hexokinase method
e)
Glucose dehydrogenase method
93.
Involves peroxidase; a color reaction enzyme
a)
Glucose Oxidase method
b)
Colorimetric Glucose Oxidase method
c)
Polarographic glucose oxidase
d)
Hexokinase method
e)
Glucose dehydrogenase method
94.
Measures the rate of Oxygen (O2) which is equal to glucose concentration
a)
Glucose Oxidase method
b)
Colorimetric Glucose Oxidase method
c)
Polarographic glucose oxidase
d)
Hexokinase method
e)
Glucose dehydrogenase method
95.
measurement of the degree of O2 consumption using a pO2 (Clark) electrode; requires addition of molybdate and iodide or catalase and ethanol to prevent reformation of O2
a)
Glucose Oxidase method
b)
Colorimetric Glucose Oxidase method
c)
Polarographic glucose oxidase
d)
Hexokinase method
e)
Glucose dehydrogenase method
96.
Involve molybdate
a)
Glucose Oxidase method
b)
Colorimetric Glucose Oxidase method
c)
Polarographic glucose oxidase
d)
Hexokinase method
e)
Glucose dehydrogenase method
97.
Most specific method for glucose measurement since its coupling reaction is highly specific; hence, the REFERENCE method
a)
Glucose Oxidase method
b)
Colorimetric Glucose Oxidase method
c)
Polarographic glucose oxidase
d)
Hexokinase method
e)
Glucose dehydrogenase method
98.
Sample: Plasma using heparin, EDTA, fluoride, Oxalate or citrate
a)
Glucose Oxidase method
b)
Colorimetric Glucose Oxidase method
c)
Polarographic glucose oxidase
d)
Hexokinase method
e)
Glucose dehydrogenase method
99.
Samples: Urine, CSF, and serous fluids
a)
Glucose Oxidase method
b)
Colorimetric Glucose Oxidase method
c)
Polarographic glucose oxidase
d)
Hexokinase method
e)
Glucose dehydrogenase method
100.
NAD/NADP = low absorbance at 340 nm
NADH/NADPH = high absorbance at 340 nm
a)
Glucose Oxidase method
b)
Colorimetric Glucose Oxidase method
c)
Polarographic glucose oxidase
d)
Hexokinase method
e)
Glucose dehydrogenase method
101.
Not affected by ascorbic acid or uric acid
a)
Glucose Oxidase method
b)
Colorimetric Glucose Oxidase method
c)
Polarographic glucose oxidase
d)
Hexokinase method
e)
Glucose dehydrogenase method
102.
NAD/NADP absorbance at 340 nm
a)
High
b)
Low
103.
NADH/NADPH absorbance at 340 nm
a)
High
b)
Low
104.
Glucose is reduced to produce a chromophore that is measure spectrophotometrically or an electrical current
a)
Glucose Oxidase method
b)
Colorimetric Glucose Oxidase method
c)
Polarographic glucose oxidase
d)
Hexokinase method
e)
Glucose dehydrogenase method
105.
Tetrazolium dye may be used to enable colorimetric-spectrophotometric measurement:
a)
Glucose Oxidase method
b)
Colorimetric Glucose Oxidase method
c)
Polarographic glucose oxidase
d)
Hexokinase method
e)
Glucose dehydrogenase method
106.
highly specific for glucose, not subject to interference from substances normally found in serum; not commonly used except in glucose POCT (glucometer)
a)
Glucose Oxidase method
b)
Colorimetric Glucose Oxidase method
c)
Polarographic glucose oxidase
d)
Hexokinase method
e)
Glucose dehydrogenase method
107.
Formed from the nonezymatic, irreversible attachment of glucose to hemoglobin A1
a)
Glycosylated hemoglobin (HbA1C)
b)
Colorimetric Glucose Oxidase method
c)
Polarographic glucose oxidase
d)
Hexokinase method
e)
Glucose dehydrogenase method
108.
It represents a "weighted" average of glucose levels
a)
Glycosylated hemoglobin (HbA1C)
b)
Colorimetric Glucose Oxidase method
c)
Polarographic glucose oxidase
d)
Hexokinase method
e)
Glucose dehydrogenase method
109.
AKA glycated hemoglobin
a)
Glycosylated hemoglobin (HbA1C)
b)
Colorimetric Glucose Oxidase method
c)
Polarographic glucose oxidase
d)
Hexokinase method
e)
Glucose dehydrogenase method
110.
Used for monitoring and diagnosis of long term glucose control
a)
Glycosylated hemoglobin (HbA1C)
b)
Colorimetric Glucose Oxidase method
c)
Polarographic glucose oxidase
d)
Hexokinase method
e)
Glucose dehydrogenase method
111.
It is useful for monitoring effectiveness of treatment and compliance of diabetic individual to treatment protocol
a)
Glycosylated hemoglobin (HbA1C)
b)
Colorimetric Glucose Oxidase method
c)
Polarographic glucose oxidase
d)
Hexokinase method
e)
Glucose dehydrogenase method
112.
Not affected by daily dietary status
a)
Glycosylated hemoglobin (HbA1C)
b)
Fructosamine
c)
Polarographic glucose oxidase
d)
Hexokinase method
e)
Glucose dehydrogenase method
113.
Aka glycosylated or glycated hemoglobin or plasma protein ketoamine
a)
Glycosylated hemoglobin (HbA1C)
b)
Fructosamine
c)
Polarographic glucose oxidase
d)
Hexokinase method
e)
Glucose dehydrogenase method
114.
Not measured in cases of low plasma albumin = liver disease
a)
Glycosylated hemoglobin (HbA1C)
b)
Fructosamine
c)
Polarographic glucose oxidase
d)
Hexokinase method
e)
Glucose dehydrogenase method
115.
HbA1C is used for monitoring and diagnosis of _term glucose control
a)
short-term
b)
long-term
116.
Fructosamine is also known for _glucose control
a)
short-term
b)
long-term
117.
HbA1C average within
a)
1 to 2 months
b)
2 to 3 months
c)
2 to 4 months
d)
3 to 6 weeks
118.
Fructosamine average within
a)
1 to 2 months
b)
2 to 3 months
c)
2 to 4 months
d)
3 to 6 weeks
119.
All of the following are methods used to detect HbA1C EXCEPT;
a)
Electrophoresis
b)
Immunoassay
c)
HPLC
d)
ISE
e)
Affinity chromatography
120.
All of the following are methods used to detect Fructosamine EXCEPT;
a)
Spectrophotometric/colorimetric methods
b)
HPLC
c)
ISE
d)
Affinity chromatography
121.
HbA1c is not suitable for patients with _ RBC lifespan disorder.
a)
Prolonged
b)
Shortened
122.
Modification of Folin-Wu method
a)
Folin Wu Method
b)
Alkaline Copper reduction method
c)
Nelson Somogyi method
d)
Neocuproine method
e)
Benedict's method
123.
Used for the detection and quantitation of reducing substances in body fluids like blood and urine
a)
Folin Wu Method
b)
Alkaline Copper reduction method
c)
Nelson Somogyi method
d)
Neocuproine method
e)
Benedict's method
124.
Stabilizing agent is citrate or tartrate
a)
Folin Wu Method
b)
Alkaline Copper reduction method
c)
Nelson Somogyi method
d)
Neocuproine method
e)
Benedict's method
125.
Yellow or yellow orange color
a)
Folin Wu Method
b)
Alkaline Copper reduction method
c)
Nelson Somogyi method
d)
Neocuproine method
e)
Benedict's method
126.
Cuprous Ions + Arseonomolybdate >> Arseonomolybdic acid or Arsenomolybdenum blue
a)
Folin Wu Method
b)
Alkaline Copper reduction method
c)
Nelson Somogyi method
d)
Neocuproine method
e)
Benedict's method
127.
Inverse colorimetry (Hagedom Jensen method)
a)
Ferric reduction
b)
Condensation
128.
(yellow orange) ferricyanide 𝑔𝑙𝑢𝑐𝑜𝑠𝑒 → (colorless) ferrocyanide
a)
Ferric reduction
b)
Condensation
129.
Dubowski method; more specific than reduction methods
a)
Ferric reduction
b)
Condensation
130.
glucose + o-toluidine → Schiff’s base (green)
a)
Ferric reduction
b)
Condensation
131.
Cuprous ions + Phosphomolybdate >> Phosphomolybdic acid or phosphomolybdenum blue
a)
Folin Wu Method
b)
Alkaline Copper reduction method
c)
Nelson Somogyi method
d)
Neocuproine method
e)
Benedict's method
132.
Principle: reduction of cupric ions to cuprous ions forming cuprous oxide in hot alkaline solution by glucose
a)
Folin Wu Method
b)
Alkaline Copper reduction method
c)
Nelson Somogyi method
d)
Neocuproine method
e)
Benedict's method
133.
Principle: reduction of cupric ions to cuprous ions forming cuprous oxide in hot alkaline solution by glucose
a)
Alkaline Copper Reduction Method
b)
Alkaline Ferric Reduction Method
c)
Chemical Methods
134.
It involves reduction of a yellow ferriccyanide to a colorless ferrocyanide by colorimetry
a)
Alkaline Copper Reduction Method
b)
Alkaline Ferric Reduction Method
c)
Chemical Methods
135.
Condensation method: Ortho-Toluidine (Dubowski method)
a)
Alkaline Copper Reduction Method
b)
Alkaline Ferric Reduction Method
c)
Chemical Methods
136.
End product of Alkaline Copper Reduction method
a)
Aeronomolybdate
b)
Phosphomolybdate
c)
Cuprous ions
137.
End product of Folin-Wu method
a)
Aeronomolybdate
b)
Phosphomolybdate
c)
Cuprous ions
100 %
